Sunshine Fixed Asset Turnover from 2010 to 2025

SBFMW Stock  USD 0.23  0.02  8.08%   
Sunshine Biopharma Fixed Asset Turnover yearly trend continues to be fairly stable with very little volatility. Fixed Asset Turnover is likely to outpace its year average in 2025. During the period from 2010 to 2025, Sunshine Biopharma Fixed Asset Turnover regression line of quarterly data had mean square error of  60.21 and geometric mean of  1.99. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
21.41
Current Value
22.48
Quarterly Volatility
10.89443623
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Slightly volatile
   Fixed Asset Turnover   
       Timeline  

Sunshine Fixed Asset Turnover Regression Statistics

Arithmetic Mean7.22
Geometric Mean1.99
Coefficient Of Variation150.97
Mean Deviation8.90
Median1.66
Standard Deviation10.89
Sample Variance118.69
Range31.9545
R-Value0.73
Mean Square Error60.21
R-Squared0.53
Significance0
Slope1.66
Total Sum of Squares1,780

Sunshine Fixed Asset Turnover History

2025 22.48
2024 21.41
2023 23.79
2022 3.76
2021 32.35
2020 3.66
2019 0.65

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 21.41  22.48 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.